Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of ginsenoside monomer Rb#[1] in the preparation process of medicine for treating myocardial ischemia and heart failure

A ginsenoside, myocardial ischemia technology, applied in cardiovascular system diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as damage to the human body, toxic side effects, etc.

Inactive Publication Date: 2005-01-26
NORTHEAST NORMAL UNIVERSITY
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have been used clinically, they all have different degrees of toxic and side effects and damage various organs of the human body, especially these drugs have not been used for heart failure and myocardial ischemia caused by endothelin-1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0006] Example 1 Rb 1 Improve endothelin-1 induced heart failure in guinea pigs in vivo

[0007] Establish several experimental dosage groups, each group of 10 adult healthy guinea pigs (300-350g) was anesthetized, opened the chest, artificially respired, inserted a polyethylene catheter (inner diameter 1.5mm) into the ventricle, and recorded the electrocardiogram synchronously with a polyconductor recorder ( ECG), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), indoor maximum rate of rise and fall (±dp / dt), heart rate (HR) and hemodynamic indicators (AF, SV, CBF). Firstly, the above normal indexes were recorded, and after 10 minutes of stabilization, endothelin-1 (37.5 μg / kg) was injected intravenously to make a heart failure model, and compared with the normal above indexes. The state of heart failure lasted for 5 minutes before injecting Rb from the vein 1 285μg / kg, the results showed that Rb 1 Significantly improved heart fai...

example 2

[0018] Example 2 Rb 1 Improvement of Endothelin-1-induced Heart Failure in Guinea Pigs

[0019] Several experimental groups were set up, with 8 adult healthy guinea pigs (300-350 g) in each group. The animals were sacrificed by disconnecting the marrow, and the heart was quickly taken out, and arterial cannulation was performed immediately for reverse perfusion. Using the Langenderff isolated perfusion method, the left ventricle was intubated. Record the left ventricular pressure, place electrodes at the apex of the heart to guide the electrocardiogram, and perform reverse perfusion for 10 minutes. 2 +5%CO 2 The pH of the mixed gas is 7.4-7.5, and the isolated heart works under the conditions of a preload of 15 cm water mark and an afterload of 70 cm water mark. Its indicators are the same as in Example 1. After stabilization, record various normal indicators as a contrast. After 10 minutes, endothelin-1 (100pmol / L) is poured into heart failure, and the above indicators are ...

example 3

[0029] Example 3 Rb 1 Improve endothelin-1 induced myocardial ischemia in rats

[0030] A number of experimental dose groups were set up, with 10 rats (400-450 g) in each group. After anesthesia, the electrocardiogram index was recorded with the second lead of the electrocardiogram. The normal index was stable for 10 minutes, and the ST segment was moved down as a reference.

[0031] Inject ET-1 (10 μg / kg) into the tail vein, take ST-segment downshift of 0.2mv as the obvious indicator of myocardial ischemia, and inject Rb after 10 minutes of stable myocardial ischemia 1 (40mg / kg), the results showed that Rb 1 Significantly improved the phenomenon of myocardial ischemia caused by endothelin-1. The results are listed in Table-3.

[0032] Table-3: Rb 1 Improve endothelin-1 induced myocardial ischemia in rats

[0033] HR ST displacement

[0034] R(mv) QRS(ms) T(mv) QT(ms)

[0035] (times) (mv)

[0036]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of ginsenoside monomer Rb#[1] in the preparation process of medicine for treating myocardial ischemia and heart failure, wherein the Rb#-[1][C#-[54]H#-[92]O#-[23]íñH#-[2]O] is used as a novel Chinese medicament for treating treating myocardial ischemia and heart failure caused by Endothelin-1 and and Isoprenaline Hydrochloride.

Description

technical field [0001] The invention belongs to the application of biological products in pharmacy. Background technique [0002] Endothelin-1 is a newly discovered biologically active substance in recent years. Excessive secretion in the body can lead to the occurrence of various diseases. In some patients with myocardial ischemia and heart failure, the content of endothelin-1 in plasma was found to be significantly higher than that of normal people, indicating that endothelin is closely related to the pathogenesis of myocardial ischemia and heart failure. At present, it is mainly through (1) inhibiting the excessive activity of neuro-humoral factors, (2) reversing cardiomyocyte apoptosis, (3) antagonizing TNFα, (4) auxin or ghrelin, (5) promoting the expression of potassium channels and Function, (6) inhibit the degradation of ANP and BNP, (7) cell transplantation to treat and heart failure. Drugs used clinically to treat myocardial ischemia can be roughly divided into s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P9/04A61P9/10
Inventor 曾庆华马越刘俊
Owner NORTHEAST NORMAL UNIVERSITY